“…The US National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III emphasizes that patients with CHD, or who have a risk of CHD and LDL cholesterol (LDL-C) levels >130 mg/dL, should receive drug therapy with a goal of reducing LDL-C to <100 mg/dL (23). To date, guinea pigs have been used to analyze the effects of numerous drug treatments, including 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (6,7,(15)(16)(17)48,51,53,54,77), Acyl-CoA:Cholesterol Acyltransferase (ACAT) inhibitors (40,46), cholestyramine (27,33,80,87), fibric acids (47,82), probucol (35), and apical sodium co-dependent bile acid transporter (ASBT) inhibitors (83,84). The growing incidence of dyslipidemia in Western societies reinforces the need for an appropriate animal model for the evaluation of cholesterol lowering drugs.…”